Increasing trend of metronidazole resistance in the treatment of Helicobacter pylori infection: A global challenge

African Journal of Biotechnology

Volumn 9, Issue 8, 2010, Pages 1115-1121

  Buta, Novosti ^a   Tanih, Nicoline F ^a   Ndip, Roland N ^a,b  

^a UNIVERSITY OF FORT HARE   (South Africa)

^b UNIVERSITY OF BUEA   (Cameroon)

Author keywords

Drug resistance; Gene mutations; Helicobacter pylori; Metronidazole; Public health

Indexed keywords

AMOXICILLIN; BISMUTH SALICYLATE; CLARITHROMYCIN; METRONIDAZOLE; NITROREDUCTASE; OXYGEN; PROTON PUMP INHIBITOR; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DEVELOPING COUNTRY; DRUG STRUCTURE; EPIGASTRIC DISCOMFORT; GENE MUTATION; HELICOBACTER INFECTION; HUMAN; NAUSEA; POPULATION; PREVALENCE; REVIEW; TASTE DISORDER; TREATMENT FAILURE;

HELICOBACTER PYLORI; NEGIBACTERIA;

EID: 77949702437     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: 10.5897/ajb2010.000-3015     Document Type: Review

References (77)

1. Abdul RA, Fikry E Abdul AA (2001). Evolution of metronidazole and tetracycline susceptibility pattern in Helicobacter pylori at a hospital in Saudi Arabia. Int. J. Antimicrob. Agents, 17(3): 233-236.
2. Abdurasheed A, Lawal OO, Abioye-kuteyi EA, Lamikanra A (2005). Antimicrobial susceptibility of Helicobacter pylori isolates of dyspeptic Nigerian patients. J. Trop. Gastroenterol. 26: 85-88.
3. Ables AZ, Simon I, Melton ER (2007). Update on Helicobacter pylori treatment. Am. Fam. Physician, 75(3): 351-358.
4. Aboderin OA, Abdul RA, Babatunde WO, Iruka NO, Oladejo OL, Ndububa DA, Agbakwuru AE, Adebayo L (2007). Antibiotic resistance of Helicobacter pylori from patients in Ile-Ife, South-west, Nigeria. Afr. Health Sci. 7: 143-147.
5. Adamek RJ, Suerbaum S, Pfatenbach B, Operkuch S (1998). Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole and amoxicillin influence on treatment outcome. Am. J. Gastroenterol. 93: 386-389.
6. Alarcon T, Domingo D, López-Brea M (1999). Antibiotic resistance problems with Helicobacter pylori: Review article. Int. J. Antimicrob. Agents, 12: 19-26
7. Al-Quarashi AR, El-Morsy F, Al-Quorain AA (2001). Evolution of metronidazole and tetracycline susceptibility pattern in Helicobacter pylori at a hospital in Saudi Arabia. Int. J. Antimicrob. Agents, 17: 233-236.
8. Asrat D, Kassa E, Mengistu Y, Nilsson I, Wadstrom T (2004). Antimicrobial susceptibility pattern of Helicobacter pylori strains isolated from adult dyspeptic patients in Tikur Ambassa University Hospital Addis Ababa. Ethiop. Med. J. 42(2): 79-85.
9. Banatvala N, Davies GR, Abdi Y, Clements L, Rampton DS, Hardie JM, Feldman RA (1994). High prevalence of Helicobacter pylori metronidazole resistance in migrants to East London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut, 35: 1562-1566.
10. Bell GD, Powell K, Burridge SM, Pallecaros A, Jones PH, Gant PW et al (Provide Complete Name) (1992). Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmnacol. Ther. 6: 427-435.
11. Cameron EAB, Powell KU, Baldwin L, Jones P, Bell GD, Williams SGJ (2004). Helicobacter pylori: antibiotic resistance and eradication rates in Suffolk, UK, 1991-2001. J. Med. Microbiol. 53: 535-538.
12. Cederbrant G, Kahlmeter G, Ljungh A (1992). Proposed mechanism for metronidazole resistance in Helicobacter pylori. J. Antimicrob. Chemother. 29: 115-120.
13. Chaudhuri S, Chowdhury A, Datta S, Mukhopadhyay AK, Chattopadhyay S, Saha DR et al. (Provide Complete Name) (2003). Anti- Helicobacter pylori therapy in India: differences in eradication efficiency associated with particular alleles of vacuolating cytotoxin (vacA) gene. J. Gastroenterol. Hepatol. 18: 190-195
14. Ching CK, Leung KP, Yung RW et al. (Provide Complete Name) (1996). Prevalence of metronidazole resistant Helicobacter pylori strains among chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut, 38: 675-678.
15. Chisholm SA, Owen RJ (2003). Mutations in Helicobacter pylori rdxA gene sequences may not contribute to metronidazole resistance. J. Antimicrob. Chemother. 51: 995-999.
16. Chisholm SA, Owen RJ (2004). Frameshift mutations in frxA occur frequently and do not provide a reliable marker for metronidazole resistance in UK isolates of Helicobacter pylori. J. Med. Microbiol. 53: 135-140.
17. Chowdhurger A, Berg DE, Jeong JY, Mukhopadhyay AK, Nair BK (2002). Metronidazole resistance in Helicobacter pylori. Magnitude, mechanism and implications for India. Indian J. Gastroenterol. 21: 23-28.
18. Clinical and Laboratory Standards Institute (CLSI) (2007). Performance standards for antimicrobial susceptibility testing; fifteenth information supplement. Wayne, PA, USA.
19. Debets-Ossenkopp YJ (1999). Insertion of mini- IS605 and deletion of adjacent sequences in the nitroreductase (rdxA) gene cause metronidazole resistance in Helicobacter pylori NCTC11637. Antimicrob. Agents Chemother. 43: 2657-2662
20. Edwards DI (1993). Nitroimidazole drugs-action and resistance mechanisms I. Mechanisms of action. J. Antimicrob. Chemother. 31: 9-20.
21. Glupczynski Y (1992). European Multicenter Study Group on antibiotic susceptibility of Helicobacter pylori. Results of a mulicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 11: 777-781.
22. Goddard AF, Logan RP (1996). Antimicrobial resistance and Helicobacter pylori. J. Antimicrob. Chemother. 37: 639-643.
23. Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idström JP, Cederberg C, Spiller RC (1996). Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastri juice. Gastroenterology, 111: 358-367.
24. Goodwin AD, Kersulyte G, Sisson SJ, Veldhuyzen van Zanten D, Berg E, Hoffman PS (1998). Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol. Microbiol. 28: 383-393.
25. Graham DY, Lew GM, Evans DG, Evans DJ, Klein PD (1991). Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann. Int. Med. 115(4): 266-269.
26. Graham DY (1998). Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology, 115: 1272-1277.
27. Hardin FJ, Wright RA (2002). Helicobacter pylori: review and update. Arch. Hosp. Physician. 38(5): 23-31.
28. Hoffman PS (1999). Antibiotic resistance mechanisms of Helicobacter pylori. Can. J. Gastroenterol. 13: 243-249.
29. Hoffman PS, Goodwin A, Johnsen J, Magee K, Veldhuyzen van Zanten SJ (1996). Metabolic activities of metronidazole-sensitive and - resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. J. Bacteriol. 178: 4822-4829
30. Jenks PJ, Ferrero RL, Labigne A (1999). The role of the rdxA gene in the evolution of metronidazole resistance in Helicobacter pylori. J. Antimicrob. Chemother. 43: 753-758.
31. Jenks PJ, Labigne A, Ferrero LR (1999). Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice. Antimicrob. Agents Chemother. 43: 777-781.
32. Jeong JY, Berg DE (2000). Mouse-colonizing Helicobacter pylori SS1 is unusually susceptible to metronidazole due to two complementary reductase activities. Antimicrob. Agents Chemother. 44(11): 3127-3132
33. Jeong JY, Mukhopadhyay AK, Dailidiene D, Wang Y, Velapatiño B, Gilman RH et al (Provide Complete Name) (2000). Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high-level metronidazole resistance in Helicobacter pylori. J. Bacteriol. 182(18): 5082-90.
34. Jeong, JY, Mukhopadhyay AK, Akada JK, Dailidiene D, Hoffman P, Berg DE (2001). Roles of FrxA and RdxA nitroreductases of Helicobacter pylori in susceptibility and resistance to metronidazole. J. Bacteriol. 183: 5155-5162.
35. Jorgensen MA et al (Provide Complete Name) (2001). Potential involvement of several nitroreductases in metronidazole resistance in Helicobacter pylori. Arch. Biochem. Biophys. 392: 180-191
36. Kaihovaara P, Höök-Nikanne J, Uusi-Oukari M, Kosunen TU, Salaspuro M (1998). Flavodoxin-dependent pyruvate oxidation, acetate production and metronidazole reduction by Helicobacter pylori. J. Antimicrob. Chemother. 41: 171-177
37. Kobayashi I, Muraoka H, Saika T, Nishida M, Fujioka T, Nasu M (2001). Antimicrobial susceptibilities of Helicobacter pylori isolates under microaerophilic atmospheres established by two different methods. J. Clin. Microbiol. 39: 2646-2647.
38. Kwon DH, El-Zaatari FA, Kato M, Osato MS, Reddy R, Yamaoka Y et al (Provide Complete Name) (2000a). Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori. Antimicrob Agents Chemother. 44(8): 2133-2142
39. Kwon DH, Kato M, El-Zaatari FA, Osato MS, Graham DY (2000b). Frame-shift mutations in NAD(P)H flavin oxidoreductase encoding gene (frxA) from metronidazole resistant Helicobacter pylori ATCC43504 and its involvement in metronidazole resistance. FEMS Microbiol. Lett. 188: 197-202
40. Kwon DH, Hulten K, Kato M, Kim JJ, Lee M, El-Zaatari FA et al (Provide Complete Name) (2001). DNA sequence analysis of rdxA and frxA from 12 pairs of metronidazole-sensitive and -resistant clinical Helicobacter pylori isolates. Antimicrob Agents Chemother. 45: 2609-2615.
41. Lamouliatte H, Talbi P, Cayla R, Zerbib F, Megraud F (1996). Randomized study comparing two seven days triple therapies with lansoprazole and low dose of clarithromycin plus amoxicillin or tinidazole for H. pylori eradication. Gut, 39(Suppl. 2): A35.
42. Loffeld RJL, Fijen F, Camp MJ (2003). Antibiotic resistance of Helicobacter pylori: a cross-sectional study in consecutive patients, and relations to ethnicity. Clin. Microbiol. Infect. 9: 600-604.
43. Lopez-Brea M, Domingo D, Sánchez I, Alarcón T (1997). Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori isolated from Spain. J. Antimicrob. Chemother. 40: 279-281.
44. Lwai-lume L, Ogutu EO, Amayo EO, Kariuki S (2005). Drug susceptibility pattern of Helicobacter pylori in patients with dyspepsia at the Kenyatta National Hospital, Nairobi. East Afr. Med. J. 82: 603-608.
45. Lesbros-Pantoflickova D, Corthesy-theulaz I, Blum AL (2007). Helicobacter pylori and Probiotics. J. Nutr. 137: 812S-818S.
46. Marais A, Bilardi C, Cantet F, Mendz GL, Megraud F (2003). Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res. Microbiol. 154: 137-144.
47. Megraud F (1997). Resistance to Helicobacter pylori to antibiotics. Aliment Pharmacol. Ther. 11(Suppl 1): 43-53
48. Megraud F, Doermann HP (1998). Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut, 43 (suppl 1): S61-S65
49. Megraud F (2004). H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut, 53(9): 1374-1384.
50. Megraud F, Lehours P (2007). Helicobacter pylori detection and antimicrobial susceptibility testing. Clin. Microbiol. Rev. 20: 280-322.
51. Mendz GL, Mégraud F (2002). Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol. 10: p. 370.
52. Meurer L, Bower D (2002). Management of Helicobacter pylori Infection. Am. Fam. Physician, 65(7): 1327-1339.
53. Ndip RN, Malange AE, Akoachere JFT, MacKay WG, Titanji VPK, Weaver LT (2004). Helicobacter pylori antigens in the faeces of asymptomatic children in the Buea and Limbe health districts of Cameroon: a pilot study. Trop. Med. Int. Health, 9(9): 1036-1040.
54. Ndip R, Malange Takang AE, Echakachi CE, Malongue A, Akoachere J-FTK, Ndip LM et al (Provide Complete Name) (2007a). In vitro antimicrobial activity of selected honeys on clinical isolates of Helicobacter pylori. Afr. Health Sci. 7(4): 228-231.
55. Ndip RN, Malange TAE, Mbulla SM, Luma HN, Agnes M, Ndip LM, Nyongbela K, Wirmum C, Efange SMN (2007b). In vitro anti-Helicobacter pylori activity of extracts of selected medicinal plants from North West Cameroon. J. Ethnopharmacol. 114: 452-457.
56. Ndip RN, Alertia EMT, Ojongokpoko JEA, Luma, HN, Malongue A, Akoachere JFTK, Ndip LM, MacMillan M, Weaver LT (2008). Helicobacter pylori isolates recovered from gastric biopsies of patients with gastro-duodenal pathologies in Cameroon: current status of antibiogram. Trop. Med. Int. Health, 13(6): 848-854.
57. Noach LA, Langenberg WL, Bertola MA, Dankert J, Tytgat GN (1994). Impact of metronidazole resistance on eradication of Helicobacter pylori. Scand. J. Infect. Dis. 26: 321-327.
58. Osato MS (2000). Antimicrobial susceptibility testing for Helicobacter pylori: sensitivity test results and their clinical relevance. Curr. Pharm. Des. 6: 1545-1555.
59. Osato MS, Reddy R, Graham DY (1999). Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int. J. Antimicrob. Agents, 12(4): 341-347.
60. Paul R, Postius S, Melchers K, Schäfer KP (2001). Mutations of the Helicobacter pylori genes rdxA and pbp1 cause resistance against metronidazole and amoxicillin. Antimicrob. Agents Chemother. 45: 962-965.
61. Salcedo JA, Al-Kawas F (1998). Treatment of Helicobacter pylori infection. Arch. Int. Med. 158: 842-851.
62. Sepulvedo AR, Coelho LGV (2002). Helicobacter pylori and gastric malignancies. Helicobacter. 7: 37-42
63. Sherif M, Zaynab M, Hanan F, Rockabrand DM, Rozmajzl PJ, Frenck RW (2004). Universal high-level primary metronidazole resistance in Helicobacter pylori isolated from children in Egypt. J. Clin. Microbiol. 42: 4832-4834.
64. Solca MM, Bernasconi MV, Piffarethi JC (2000). Mechanism of metronidazole resistance in Helicobacter pylori: comparison of the rdxA gene sequences of 30 strains. Antimicrob. Agents Chemother. 44: 2207-2210.
65. Smith SI, Oyedeji KS, Arigbabu,AO, Atimomo C, Coker AO (2001). High amoxicillin resistance in Helicobacter pylori from gastritis and peptic ulcer patients in western Nigeria. J. Gastroenterol. 36: 67-68.
66. Suerbaum S, Michetti P (2002). Helicobacter pylori infection. N. Engl. J. Med. 347: 1175-1186.
67. Tanih NF, Dube C, Green E, Mkwetshana N, Clarke AM, Ndip LM, Ndip RN (2009). An African perspective on Helicobacter pylori: prevalence of human infection, drug resistance, and alternative approaches to treatment. Ann. Trop. Med. Parasitol. 103: 189-204.
68. Tanih NF, Okeleye BI, Naido N, Clarke AM, Mkweshana N, Green E, Ndip LM, Ndip RN (2010). Marked susceptibility of South African Helicobacter pylori strains to ciprofloxacin and amoxicillin: Clinical implication. S. Afr. Med. J. 100 (1): 49-52.
69. Tankovic JD, Lamarque JC, Delchier CJ, Soussy A, Labigne C, Jenks PJ (2000). Frequent association between alteration of the rdxA gene and metronidazole resistance in French and North African isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 44: 608-613.
70. Thyagarajan SP, Dharmalingam S, Rao UA, Jayaraman G (2003). Relationship of plasmid profile with the antibiotic sensitivity pattern of Helicobacter pylori isolates from peptic ulcer disease patients in Chennai. Indian J. Med. Microbiol. 21(4): 257-261.
71. Van der Wouden EJ, Thijs JC, Kusters JG, van Zwet AA, Kleibeuker JH (2001). Mechanism and clinical significance of metronidazole resistance in Helicobacter pylori. Scand. J. Gastroenterol. 234: 10-14.
72. Van der Wouden EJ, Thijs JC, van Zwet AA, Kleibeuker JH (2000). Nitroimdazole resistance in Helicobacter pylori: a review. Aliment Pharmacol. Ther. 14(1): 7-14.
73. Van der Wouden EJ, van Zwet AA, Vosmaer GD, Oom JA, de Jong A, Kleibeuker JH (1997). Rapid increase in the prevalence of metronidazole resistant Helicobacter pylori in The Netherlands. Emerg. Infect. Dis. 3: 385-389.
74. Vasques A, Valdez Y, Gilman RH, McDonald JJ, Westblom TU, Berg D, Mayta H, Gutierrez V (1996). Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. J. Clin. Microbiol. 34: 1232-1234.
75. Veldhuyzen van Zanten S, Hunt RH, Cockeram A, Schep G, Malatjalian D, Sidorov J, Matisko A, Jellell D (1998). Adding once-daily omeprazole 20mg to metronidazole/amoxycillin treatment for Helicobacter pylori gastritis: A randomized, doubleblind trial showing the importance of metronidazole resistance. Am. J. Gastroenterol. 93: 5-10.
76. Wang WH, Wong BC, Mukhopadhyay AK, Berg DE, Cho CH, Lai KC, Hu WH, Fung,FM, Hui WM, Lam SK (2000). High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment. Pharmacol. Ther. 14: 901-910.
77. Wong BCY, Chang FY, Abid S, Abbas Z, Lin BR, van Rensburg C, Chen PC, Schneider H, Simjee AE, Hamid SS, Seebaran A, Zhang J, Destefano M (2000). Triple therapy with clarithromycin, omeprazole and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment Pharmacol. Ther. 4: 1529-1535.